Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly
Paul Fellinger, … , Michael Krebs, Yvonne Winhofer
Paul Fellinger, … , Michael Krebs, Yvonne Winhofer
Published February 27, 2020
Citation Information: JCI Insight. 2020;5(5):e134638. https://doi.org/10.1172/jci.insight.134638.
View: Text | PDF
Research Article Endocrinology Metabolism

Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly

  • Text
  • PDF
Abstract

Patients with active acromegaly (ACRO) exhibit low hepatocellular lipids (HCL), despite pronounced insulin resistance (IR). This contrasts the strong association of IR with nonalcoholic fatty liver disease in the general population. Since low HCL levels in ACRO might be caused by changes in oxidative substrate metabolism, we investigated mitochondrial activity and plasma metabolomics/lipidomics in active ACRO. Fifteen subjects with ACRO and seventeen healthy controls, matched for age, BMI, sex, and body composition, underwent 31P/1H-7-T MR spectroscopy of the liver and skeletal muscle as well as plasma metabolomic profiling and an oral glucose tolerance test. Subjects with ACRO showed significantly lower HCL levels, but the ATP synthesis rate was significantly increased compared with that in controls. Furthermore, a decreased ratio of unsaturated-to-saturated intrahepatocellular fatty acids was found in subjects with ACRO. Within assessed plasma lipids, lipidomics, and metabolomics, decreased carnitine species also indicated increased mitochondrial activity. We therefore concluded that excess of growth hormone (GH) in humans counteracts HCL accumulation by increased hepatic ATP synthesis. This was accompanied by a decreased ratio of unsaturated-to-saturated lipids in hepatocytes and by a metabolomic profile, reflecting the increase in mitochondrial activity. Thus, these findings help to better understanding of GH-regulated antisteatotic pathways and provide a better insight into potentially novel therapeutic targets for treating NAFLD.

Authors

Paul Fellinger, Peter Wolf, Lorenz Pfleger, Patrik Krumpolec, Martin Krssak, Kristaps Klavins, Stefan Wolfsberger, Alexander Micko, Patricia Carey, Bettina Gürtl, Greisa Vila, Wolfgang Raber, Clemens Fürnsinn, Thomas Scherer, Siegfried Trattnig, Alexandra Kautzky-Willer, Michael Krebs, Yvonne Winhofer

×

Figure 1

7-T MR spectroscopy of the liver.

Options: View larger image (or click on image) Download as PowerPoint
7-T MR spectroscopy of the liver.
7-Tesla MR examinations in patients wi...
7-Tesla MR examinations in patients with active acromegaly (ACRO, n = 12) and healthy controls (CON, n = 17) showed (A) significantly decreased HCL (ACRO 1.0% [0.7%–1.8%] vs. CON 2.8% [1.5%–12.4%]) using Mann-Whitney U test (median ± IQR); (B) a lower unsaturation index in the liver (ACRO 8.4% [0.6%–16.3%] vs. CON 25.5% [18.9%–32.2%]) using a multivariable model adjusting for HCL (adjusted mean ± 95% CI); and (C) significantly increased hepatic ATP synthase activity (ACRO (0.28 s–1 [0.22–0.34 s–1] vs. CON 0.19 s–1 [0.14–0.24 s–1]), using a multivariable model adjusting for HCL (adjusted mean ± 95% CI). HCL, hepatocellular lipid content.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts